GreenLight Biosciences (GRNA) Form 4 GreenLight Biosciences Holdings, PBC / CAROLE B COBB ownership change

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burden
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

COBB CAROLE B

(Last) (First) (Middle)

C/O GREENLIGHT BIOSCIENCES HOLDINGS, PBC

200 BOSTON AVENUE, SUITE 3100

(Street)

MEDFORD MA 02155

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
GreenLight Biosciences Holdings, PBC [ GRNA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2022

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$0.35	02/02/2022		A		427,752		(1)	07/22/2025	Common Stock	427,752	(2)	427,752	D
Stock Option (Right to Buy)	$0.35	02/02/2022		A		43,863		(3)	10/21/2026	Common Stock	43,863	(2)	43,863	D
Stock Option (Right to Buy)	$0.33	02/02/2022		A		459,264		(4)	02/14/2028	Common Stock	459,264	(2)	459,264	D
Stock Option (Right to Buy)	$0.33	02/02/2022		A		187,831		(5)	09/13/2028	Common Stock	187,831	(2)	187,831	D
Stock Option (Right to Buy)	$0.5	02/02/2022		A		480,560		(6)	12/29/2029	Common Stock	480,560	(2)	480,560	D
Stock Option (Right to Buy)	$0.5	02/02/2022		A		26,987		(6)	12/29/2029	Common Stock	26,987	(2)	26,987	D
Stock Option (Right to Buy)	$0.98	02/02/2022		A		326,144		(7)	12/01/2030	Common Stock	326,144	(2)	326,144	D

Explanation of Responses:

1. 25% of the shares underlying the option vested or shall vest on July 23, 2016, and the remainder of the shares vested or shall vest in 48 equal monthly installments thereafter, starting August 23, 2016.

2. This option was issued pursuant to the terms of a business combination agreement involving the Issuer and GreenLight Biosciences, Inc. in exchange for a comparable option previously issued by such company.

3. 20% of the shares underlying the option vested or shall vest on October 21, 2017, and the remainder of the shares vested or shall vest in 48 equal monthly installments thereafter, starting November 21, 2017.

4. 20% of the shares underlying the option vested or shall vest on September 12, 2018, and the remainder of the shares vested or shall vest in 48 equal monthly installments thereafter, starting October 12, 2018.

5. 20% of the shares underlying the option vested or shall vest on May 30, 2019, and the remainder of the shares vested or shall vest in 48 equal monthly installments thereafter, starting June 30, 2019.

6. 20% of the shares underlying the option vested or shall vest on December 5, 2020 and the remainder of the shares vested or shall vest in 48 equal monthly installments thereafter, starting January 5, 2021.

7. 25% of the shares underlying the option vested or shall vest on December 1, 2021 and the remainder of the shares vested or shall vest in 36 equal monthly installments thereafter, starting January 1, 2022.

	/s/David Kennedy, Attorney-in-fact	02/04/2022
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.